Bristol-Myers Squibb, Ventiv ink multi-year service deal

Share this article:
Bristol-Myers Squibb and Ventiv Pharma Services have signed a multi-year service agreement under which Ventiv will provide a sales force of more than 375 representatives focusing on Cefzil and Tequin.
Under the terms of the agreement, Ventiv Pharma also will provide BMS with the entire field and internal management staff, full operational support to include sales force automation, help desk support and analysis and reporting services, according to a Ventiv statement. Ventiv Pharma is a division of Ventiv Health Inc.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.